Vertex Pharmaceuticals Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 0QZU.L | BIIB | KRYS | SION | PTCT | VIR | |
|---|---|---|---|---|---|---|
| Market cap | — | 35.61B | 9.54B | 174.73M | 5.23B | 1.79B |
| P/E (TTM) | 55.0 | 42.8 | 40.4 | — | — | — |
| Forward P/E | — | 14.6 | 36.0 | -1.7 | 26.4 | -4.2 |
| Price/book | 6.5 | 1.9 | 7.0 | 0.7 | -31.5 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +37.54% | +64.57% | +74.56% | −89.33% | −5.41% | +75.49% |
| Today | +2.07% | −0.87% | −1.00% | −6.75% | −0.48% | −1.58% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All 0QZU.L news ›AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Choosing between established dividend payers and high-growth innovators is a classic investor dilemma. This comparison pits AbbVie (ABBV +2.26%) against Vertex Pharmaceuticals (VRTX +2.53%) to determine which company offers the best…
How Vertex Pharmaceuticals Incorporated (VRTX) Affects Rotational Strategy Timing
Stock Traders Daily Key findings for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) - Weak Near and Mid-Term Sentiment Could Challenge Long-Term Positive Outlook - Exceptional 25.9:1 risk-reward short setup targets 7.5% downside vs…
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653
www.marketscreener.com Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 Published on 10/15/2026 at 06:40 am EDT
Vertex Pharmaceuticals Incorporated Presents New Interim Data on Alyftrek in Children Ages 2 to 5 Years At the North American Cystic Fibrosis Conference
Vertex Pharmaceuticals Incorporated announced new interim data from the ALYFTREK® 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children...
DC Circuit Agrees Vertex Pharmaceuticals’ Fertility Support Program Would Violate Anti-Kickback Statute
On September 4, the US Court of Appeals for the DC Circuit ruled that the US Department of Health and Human Services Office of the Inspector General (HHS-OIG) properly found that Vertex Pharmaceuticals’ Fertility Support Program would…
Vertex Pharmaceuticals announces $10 billion acquisition: Can VRTX reverse weak momentum?
Traders Union
Why Vertex Pharmaceuticals (VRTX) Stock Is Down Today
$VRTX insiders have traded $VRTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales. We have seen 855 institutional investors add shares of $VRTX stock to their portfolio,…
Vertex Pharmaceuticals (VRTX) Reports Promising ALYFTREK Study Results in Young Children with Cystic Fibrosis
What is VRTX's GF Score™? VRTX’s GF Score™ is 87 out of 100, indicating a high-quality company with strong financial strength, profitability, and valuation metrics, though momentum is relatively weaker. Is VRTX overvalued or undervalued?…
Reviewing Vertex Pharmaceuticals (NASDAQ:VRTX) and Caribou Biosciences (NASDAQ:CRBU)
Posted by Sarita Garza on Oct 8th, 2026 Caribou Biosciences (NASDAQ:CRBU – Get Free Report) and Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the…
Vertex Pharmaceuticals Incorporated: Latest Headlines - Nasdaq Stock Exchange
Find the latest highlights on Vertex Pharmaceuticals Incorporated at the Nasdaq stock exchange. Highlights Vertex Pharmaceuticals Incorporated All financial news and data tailored to specific country editions
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com7
-
fool.com3
-
gurufocus.com2
-
bitget.com1
-
news.stocktradersdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 19 articles, not a forecast.